Peptide Comparison
Semaglutide vs Retatrutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Semaglutide has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Semaglutide is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Semaglutide | Retatrutide | |
|---|---|---|
| Class | GLP-1 receptor agonist | GIP/GLP-1/glucagon triple agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion [1][2] | Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects |
| Route | SC injection / Oral | SC injection |
| Half-life | ~7 days | ~6 days |
| Dosage (research) | 0.25 mg SC weekly (Wegovy/Ozempic label starting dose, escalate monthly to label max 2.4 mg weekly per STEP-1 protocol) [1][2][3]; oral 3 mg daily Rybelsus starting dose (target 14 mg daily) | 2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk) |
| Evidence tier | FDA-Approved | Phase 3 |
| Research depth | 624 indexed | 217 indexed |
| Availability | Prescription | Investigational |
| Reported risks | Nausea; vomiting; constipation; pancreatitis; gallbladder disease; thyroid C-cell tumor warning [1][2] | GI side effects; Phase 3 ongoing; long-term safety unknown |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Semaglutide or Retatrutide?
Semaglutide has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Semaglutide is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Semaglutide and Retatrutide?
Semaglutide is classed as GLP-1 receptor agonist; Retatrutide is classed as GIP/GLP-1/glucagon triple agonist. Reported mechanism: Semaglutide, GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion; Retatrutide, Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects. Reported half-life: Semaglutide, ~7 days; Retatrutide, ~6 days. Routes in published studies: Semaglutide, SC injection / Oral; Retatrutide, SC injection.
Which has stronger evidence, Semaglutide or Retatrutide?
Semaglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Semaglutide is graded FDA-Approved, with 104 cited sources on its reference page and 624 indexed studies. Retatrutide is graded Phase 3, with 29 cited sources on its reference page and 217 indexed studies.
Which is more accessible, Semaglutide or Retatrutide?
Semaglutide is FDA-approved and Retatrutide is not. Catalog status: Semaglutide, Prescription; Retatrutide, Investigational.
Are Semaglutide and Retatrutide ever combined?
Semaglutide and Retatrutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…